Fig. 3
From: A polymeric nanocarrier that eradicates breast cancer stem cells and delivers chemotherapeutic drugs
Evaluation of the BCC-targeted capacity of DOX/HA-b-PCDA NPs in vitro. A, B The uptake of DOX/HA-b-PCDA NPs and free DOX in 4T1 BCCs (A) and 293 T cells (B) observed by fluorescence microscope, scale bar = 100 μm. C Intracellular distribution of DOX/HA-b-PCDA NPs in 4T1 BCCs observed by CLSM, for observation, the nuclei were stained with DAPI (blue), lysosome were stained with lysosome tracker (Green), scale bar = 20 μm. D The mean fluorescence intensity of DOX in 4T1 BCCs and 293 T cells after incubation with DOX solution or DOX/HA-b-PCDA NPs solution. E The mean fluorescence intensity of DOX in 4T1 BCCs after incubation with DOX solution or DOX/HA-b-PCDA NPs solution with or without pre-incubation with 1 mM of HA solution. “***”, p < 0.001